Invasive pulmonary aspergillosis real-world outcomes: Clinical features and risk factors associated with increased mortality

被引:11
|
作者
Henao-Martinez, Andres F. [1 ,5 ]
Corbisiero, Michaele Francesco [1 ]
Salter, Ixchel [1 ]
Chastain, Daniel B. [2 ]
Thompson III, George R. [3 ,4 ]
机构
[1] Univ Colorado, Dept Med, Div Infect Dis, Anschutz Med Campus, Aurora, CO 80045 USA
[2] Univ Georgia, Dept Clin & Adm Pharm, Coll Pharm, Albany, GA 31701 USA
[3] Univ Calif Sacramento, Davis Med Ctr, Dept Med, Div Infect Dis, Sacramento, CA 95817 USA
[4] Univ Calif Sacramento, Davis Med Ctr, Dept Med Microbiol & Immunol, Sacramento, CA 95817 USA
[5] Univ Colorado, Anschutz Med Campus, 12700,19th Ave,Mail Stop B168, Aurora, CO 80045 USA
关键词
Aspergillus; invasive pulmonary aspergillosis; mortality; drug therapy; VORICONAZOLE; INFECTIONS; DIAGNOSIS; PHASE-3;
D O I
10.1093/mmy/myad074
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Invasive pulmonary aspergillosis (IPA) is a severe fungal infection that primarily affects immunocompromised patients and is associated with high mortality. Contemporary clinical characteristics of IPA and "real-world" estimates and predictors of associated mortality are inadequate. TriNetX, a global research network, was queried to identify adult patients with IPA diagnoses based on the ICD-10 code B44.0. We performed a propensity score-matched analysis comparing clinical characteristics among patients who survived versus non-survivors at 1 year. We identified 4371 patients with IPA. We found neoplasms, solid organ transplant recipients, hematologic malignancies, and aplastic anemia as the most predominant risk factors. The overall 1-year mortality was 32% for IPA. 1-year mortality was highest for patients with COVID-19 in the ICU, followed by those with acute myeloid leukemia and aplastic anemia (54%, 50%, and 39%, respectively). After propensity score matching, severe sepsis, pleural effusion, and candidiasis were mortality contributors within a year after diagnosis. Liver injury, systemic glucocorticoid exposure over the previous 6 months, lower lymphocyte and CD4 counts, elevated ferritin, LDH, thrombocytopenia, anemia, or elevated glycosylated hemoglobin (HbA1c) were independent predictors of mortality at 1 year. Voriconazole was the most common treatment (67%). The annual incidence of IPA was 0.001%, increasing to 0.02% among critically ill patients in the ICU. IPA continues to have a very high mortality. We encourage prospective studies to validate and refine the identified clinical markers linked to increased mortality. Lay Summary Invasive pulmonary aspergillosis (IPA) is common among immunocompromised patients. Analyzing a global research network, we found 32% of patients with IPA died a year after diagnosis. We identified the primary underlying conditions, contributors, and predictors of mortality.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: Clinical presentation, risk factors, and outcomes
    Zhang, Xuan
    Yang, Meifang
    Hu, Jianhua
    Zhao, Hong
    Li, Lanjuan
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (02) : 819 - 827
  • [2] Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes
    Dandachi, Dima
    Dib, Rita Wilson
    Fernandez-Cruz, Ana
    Jiang, Ying
    Chaftari, Anne-Marie
    Hachem, Ray
    Raad, Issam
    ANNALS OF MEDICINE, 2018, 50 (08) : 713 - 720
  • [3] Risk factors for development and mortality of invasive pulmonary Aspergillosis in kidney transplantation recipients
    Seok, Hyeri
    Huh, Kyungmin
    Cho, Sun Young
    Kang, Cheol-In
    Chung, Doo Ryeon
    Huh, Woo Seong
    Park, Jae Berm
    Peck, Kyong Ran
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2020, 39 (08) : 1543 - 1550
  • [4] Comparison of Clinical Manifestation, Diagnosis, and Outcomes of Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis
    Lin, Chun-Yu
    Wang, I-Ting
    Chang, Che-Chia
    Lee, Wei-Chun
    Liu, Wei-Lun
    Huang, Yu-Chen
    Chang, Ko-Wei
    Huang, Hung-Yu
    Hsiao, Hsuan-Ling
    Kao, Kuo-Chin
    Huang, Chung-Chi
    Dimopoulos, George
    MICROORGANISMS, 2019, 7 (11)
  • [5] FACTORS ASSOCIATED WITH UNFAVORABLE TREATMENT OUTCOMES IN INVASIVE PULMONARY ASPERGILLOSIS (IPA) IN NORTHEASTERN THAILAND
    Reechaipichitkul, Wipa
    Suttayamook, Teeraporn
    Chaimanee, Prajuab
    Kularbkaew, Churairat
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2019, 50 (06) : 1139 - 1147
  • [6] Clinical features and risk factors of invasive pulmonary aspergillosis in interstitial lung disease patients
    Liu, Yin
    Jiang, Hanyi
    Zhao, Tingting
    Cao, Min
    He, Jian
    Qi, Rongfeng
    Xiao, Yonglong
    Su, Xin
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [7] Risk factors for development and mortality of invasive pulmonary Aspergillosis in kidney transplantation recipients
    Hyeri Seok
    Kyungmin Huh
    Sun Young Cho
    Cheol-In Kang
    Doo Ryeon Chung
    Woo Seong Huh
    Jae Berm Park
    Kyong Ran Peck
    European Journal of Clinical Microbiology & Infectious Diseases, 2020, 39 : 1543 - 1550
  • [8] Clinical risk factors for invasive aspergillosis
    Baddley, John W.
    MEDICAL MYCOLOGY, 2011, 49 : S7 - S12
  • [9] Risk factors and outcomes in lung transplant recipients with nodular invasive pulmonary aspergillosis
    Singh, Nina
    Suarez, Jose F.
    Avery, Robin
    Lass-Floerl, Cornelia
    Geltner, Christian
    Pasqualotto, Alessandro C.
    Lyon, G. Marshall
    Barron, Michelle
    Husain, Shahid
    Wagener, Marilyn M.
    Montoya, Jose G.
    JOURNAL OF INFECTION, 2013, 67 (01) : 72 - 78
  • [10] Treatment pathways, switches, and inappropriate treatment during invasive pulmonary aspergillosis: real-world experiences from a global research network study
    Henao-Martinez, Andres F.
    Chastain, Daniel B.
    Thompson, George R., III
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (10)